Clinigen Group (CLIN) Receives “Buy” Rating from Peel Hunt

Clinigen Group (LON:CLIN)‘s stock had its “buy” rating reiterated by analysts at Peel Hunt in a report released on Thursday.

Separately, Numis Securities reaffirmed a “buy” rating on shares of Clinigen Group in a research note on Wednesday, July 25th. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of GBX 1,260.60 ($16.42).

CLIN stock opened at GBX 887.85 ($11.57) on Thursday. Clinigen Group has a one year low of GBX 751.50 ($9.79) and a one year high of GBX 1,187 ($15.46).

Clinigen Group Company Profile

Clinigen Group plc operates as a specialty pharmaceutical and services company. Its Clinigen Clinical Trial Services segment supplies and manages commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. The company's Idis Managed Access segment is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies.

See Also: Do Tariffs Work?

Analyst Recommendations for Clinigen Group (LON:CLIN)

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply